leisure time -WSS

leisure time

author：leisure time 2025-10-01 04:45:03 - browse：8259

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

entertainment

WSS

Woman returns to dialysis after doctors remove transplanted pig kidney

What's changing in Medicare's open enrollment this year?

European regulators consider appeal over Amylyx ALS drug

Medicare to cover more brain scans related to Alzheimer’s drugs

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Peter Marks talks Operation Warp Speed for Rare Diseases

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Peter Hotez and the public health issue of online harassment

European regulators consider appeal over Amylyx ALS drug

In age of alternative facts, a scholarly course on calling out crap

What's changing in Medicare's open enrollment this year?

Medical leaders decry Supreme Court decision on affirmative action

FDA's Pazdur wants cancer trials to range beyond China alone

Medical leaders decry Supreme Court decision on affirmative action

Cord blood banking comes at a high cost to babies

Supreme Court strikes down use of affirmative action

A fraught question for the kids of Alzheimer’s: Is it coming for us?

hotspot

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

STAT Readout Newsletter: Today in biotech, life science news

Intellia reports positive results for its CRISPR

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

ASCO: Palliative care found as helpful given virtually as in person

entertainment

knowledge

entertainment

entertainment